Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the multiplex biomarker imaging market grown in recent years?

The market for multiplex biomarker imaging has seen significant growth in the past few years. The market size is projected to expand from $0.49 billion in 2024 to $0.54 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 11.0%. This growth trajectory during the historical period is due to factors such as the rising incidence of cancer, the demand for accurate diagnostic instruments, the increasing prevalence of chronic illnesses, growth in the elderly population, and the trend towards personalized medicine.

How is the multiplex biomarker imaging market size expected to evolve during the forecast period?

The market size of multiplex biomarker imaging is predicted to expand rapidly in the coming years, reaching a valuation of $0.82 billion by 2029 at a compound annual growth rate (CAGR) of 10.8%. The predicted growth during the forecast period can be ascribed to factors such as the increasing focus on personalized medicine, escalated research and development activities, a rise in clinical trials, the demand for high throughput screening methods in drug discovery, as well as supportive regulatory frameworks and guidelines. The upcoming trends for the forecast period include improvements in technology, breakthroughs in imaging technologies, progression in digital pathology, advancements in imaging software and data analysis, and the incorporation of artificial intelligence (AI) and machine learning into imaging technologies.

Get your multiplex biomarker imaging market report here!

https://www.thebusinessresearchcompany.com/report/multiplex-biomarker-imaging-global-market-report

Which key drivers are propelling the multiplex biomarker imaging market’s growth?

The multiplex biomarker imaging market’s expansion is anticipated to be driven by the increasing occurrence of chronic ailments. These are enduring health issues that repeatedly resurface over a prolonged period and are typically associated with intricate etiologies, multiple hazard factors, and extended latency intervals. A variety of factors have resulted in a growing rate of chronic disorders, including a swiftly aging populace, augmented case identification and detection, enhanced disease treatment and management, as well as changes in lifestyle and environmental risk elements. Multiplex biomarker imaging plays a crucial role in managing chronic illnesses by providing a thorough analysis and characterization of disease progression and treatment outcome. For instance, a report published by the National Institutes of Health (NIH), a biomedical research entity based in the US, revealed in January 2023 that the count of individuals aged 50 and above suffering from at least one chronic disease is projected to surge by 99.5%, from 71.52 million in 2020 to 142.66 million in 2050. Consequently, the increasing incidence of chronic illnesses is fueling the growth of the multiplex biomarker imaging market.

What are the market segments in the multiplex biomarker imaging industry?

The multiplex biomarker imaging market covered in this report is segmented –

1) By Component Type: Instruments, Software, Services

2) By Imaging Techniques: Immuno Fluorescence (IF) Assay, Tissue Microarray (TMA) Assay, Immunohistochemistry (IHC) Assay, Fluorescent In The Situ Hybridization (FISH) Assay, Toponome Imaging System (TIS)

3) By Application: Drug Safety, Oncology Studies, Genetic Characterization Studies

4) By End User: Research Institutes Government And Private, Clinical Labs, Pharmaceutical And Biotechnology

Subsegments:

1) By Instruments: Imaging Systems (Microscopes, Scanners), Detection Devices (Sensors, Probes), Reagents And Kits

2) By Software: Image Analysis Software, Data Management Software, Visualization And Interpretation Software

3) By Services: Technical Support And Maintenance, Consultation And Training, Imaging And Analysis Services

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16127&type=smp

Which leading companies are shaping the growth of the multiplex biomarker imaging market?

Major companies operating in the multiplex biomarker imaging market are Merck KGaA, Thermo Fisher Scientific Inc., Danaher corporation, Becton Dickinson and Company (BD), Carl Zeiss AG, Illumina Inc, PerkinElmer Inc., Bio-Rad Laboratories Inc, Bruker Corporation, Bio-Techne Corporation, Leica Biosystems Nussloch GmbH, Abcam Plc, Meso Scale Diagnostics LLC, Fluidigm Corporation, NanoString Technologies, Quanterix Corporation, Akoya Biosciences, Enzo Biochem Inc, Cisbio Bioassays, Flagship Biosciences, Aushon BioSystems Ltd, Ionpath Inc., Biosims Technologies

What key trends are currently impacting the multiplex biomarker imaging market’s development?

Prominent entities in the multiplex biomarker imaging market are concentrating on the development of resourceful slides like automated slide loaders. These advanced imaging solutions benefit consumers by minimizing manual handling and boosting throughput – key factors in high-volume multiplex biomarker imaging studies. For example, in April 2024, Standard BioTools Inc., a US-based firm that specializes in analytical systems and instruments, introduced the Hyperion XTi Imaging System. This innovation featured a new high-throughput multiplexed whole slide, increasing automation and adaptability. With its three modes of analysis, including preview, tissue, and cell modes, this system allows researchers to rapidly identify tissue diversity and perform in-depth examinations. This advanced whole slide imaging technique, using imaging mass cytometry (IMC), is up to 10 times more efficient than cyclic immunofluorescent imaging. Furthermore, the new automated slide loader encourages high-throughput imaging and reduces manual handling, standardizing the process. These enhancements are intended to expedite spatial proteomics developments, offering dependable insights into health and disease.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16127

Which geographic areas are influencing the growth of the multiplex biomarker imaging market?

North America was the largest region in the multiplex biomarker imaging market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiplex biomarker imaging market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report

Cardiac Biomarkers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report

Oncology Biomarkers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: